var data={"title":"Certolizumab pegol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Certolizumab pegol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/352290?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=certolizumab-pegol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Certolizumab pegol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027445\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with certolizumab are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab should be discontinued if a patient develops a serious infection or sepsis. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before certolizumab use and during therapy. Treatment for latent infections should be initiated prior to certolizumab use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risks and benefits of treatment with certolizumab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with certolizumab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers. Certolizumab is not indicated for use in pediatric patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6019485\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cimzia;</li>\n      <li>Cimzia Prefilled;</li>\n      <li>Cimzia Starter Kit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9477197\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cimzia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027450\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Gastrointestinal Agent, Miscellaneous;</li>\n      <li>\n        Tumor Necrosis Factor (TNF) Blocking Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027509\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Each 400 mg dose should be administered as 2 injections of 200 mg each</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b> SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose; Maintenance: 200 mg every 2 weeks or 400 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose; Maintenance: 400 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b> SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose; Maintenance: 200 mg every other week. May consider maintenance dose of 400 mg every 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose; Maintenance: 200 mg every other week.  May consider maintenance dose of 400 mg every 4 weeks. May be administered alone or in combination with methotrexate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027510\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7822930\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); pharmacokinetics of the pegylated (polyethylene glycol) component of certolizumab is expected to be dependent on renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682568\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20134470\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity, lupus-like syndrome, serious infection, sepsis, or hepatitis B reactivation: Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027523\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cimzia: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cimzia Prefilled: 200 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cimzia Starter Kit: 6 X 200 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027448\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874551\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf#page=33&amp;token=opRKh0WmkHLPQy8WUmW6c0hy7dcOLzPo8A1VbGs0U0FVdYiH9Zozu9sKSoCRZpRinofw3o4u/InzNpYdrkcRb/fYmq/QXzwD0ccPOzAD/tUS5BugACHNajMcW3VXbXxI&amp;TOPIC_ID=11748\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf#page=33</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027511\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Bring to room temperature prior to administration. After reconstitution (of vials), draw each vial into separate syringes (using 20-gauge needles).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer subcutaneously (using provided 23-gauge needle) into the abdomen or thigh. For a 400 mg (2 syringes) dose, administer each 200 mg syringe at a separate site; rotate injection sites. Do not administer to areas where skin is tender, bruised, red, or hard.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027452\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b> Treatment of adults with active ankylosing spondylitis (AS)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> Treatment of moderately to severely active Crohn disease in patients who have inadequate response to conventional therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b> Treatment of adult patients with active psoriatic arthritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Treatment of adults with moderately to severely active rheumatoid arthritis (RA) (as monotherapy or in combination with nonbiological disease-modifying antirheumatic drugs [DMARDS])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24744596\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Certolizumab pegol may be confused with sarilumab.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cimzia may be confused with Cyramza</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027462\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;11% [Schreiber 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (7% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (38%; serious: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (6% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&le;5%), angina pectoris (&lt;5%), atrial fibrillation (&lt;5%), cardiac arrhythmia (&lt;5%), cardiac failure (&lt;5%; new or worsening), cerebrovascular accident (&lt;5%), hypertensive heart disease (&lt;5%), ischemic heart disease (&lt;5%), myocardial infarction (&lt;5%), pericardial effusion (&lt;5%), pericarditis (&lt;5%), transient ischemic attacks (&lt;5%), vasculitis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5%), anxiety (&lt;5%), bipolar mood disorder (&lt;5%), suicidal tendencies (&lt;5%), fatigue (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;9%), alopecia (&lt;5%), dermatitis (&lt;5%), erythema nodosum (&lt;5%), urticaria (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&le;8%), nephrotic syndrome (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&lt;5%), hemorrhage (&lt;5%), hypercoagulability state (&lt;5%), leukopenia (&lt;5%), lymphadenopathy (&lt;5%), pancytopenia (&lt;5%), thrombophlebitis (&lt;5%), positive ANA titer (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatitis (&lt;5%), increased serum transaminases (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (6% to 7%), back pain (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Optic neuritis (&lt;5%), retinal hemorrhage (&lt;5%), uveitis (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (&le;6%), nasopharyngitis (5%), tuberculosis (&lt;5%; peritoneal, pulmonary, and disseminated), bronchitis (&le;3%), pharyngitis (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, aplastic anemia, autoimmune hepatitis (Shelton 2015), cytopenia, demyelinating disease (exacerbation), diarrhea, fistula, hepatosplenic T-cell lymphoma, herpes virus infection, hypersensitivity reaction (eg, allergic dermatitis, angioedema, dizziness [postural], dyspnea, hepatotoxicity (idiosyncratic) (Chalasani 2014), hot flush, hypotension, injection site reactions, malaise, serum sickness, syncope), intestinal obstruction, leukemia, limb pain, lupus erythematosus, lupus-like syndrome, lymphoma, malignant melanoma, malignant neoplasm, Merkel cell carcinoma, neoplasm (benign, malignant, and unspecified; including cysts and polyps), opportunistic infection (rare), peripheral edema, peripheral neuropathy, pneumonia, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pyelonephritis, reactivation of HBV, sarcoidosis, seizure, sensory disturbance, thrombocytopenia, viral infection, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027458\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to certolizumab or any component of the formulation; active tuberculosis or other severe infections (eg, sepsis, abscesses, opportunistic infections); moderate to severe heart failure (NYHA Class III/IV).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027459\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Autoantibody formation may develop; rarely resulting in autoimmune disorder, including lupus-like syndrome; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating CNS disease: Rare cases of optic neuritis, seizure, peripheral neuropathy, and demyelinating disease (eg, multiple sclerosis, Guillain-Barr&eacute; syndrome; new onset or exacerbation) have been reported. Use with caution in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Rare cases of pancytopenia and other significant cytopenias, including aplastic anemia, have been reported with TNF-blocking agents. Leukopenia and thrombocytopenia have occurred with certolizumab. Consider discontinuing therapy with significant hematologic abnormalities. Use with caution in patients with underlying hematologic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Rare reactivation of hepatitis B virus (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients. Patients who test positive for HBV surface antigen should be referred for hepatitis B evaluation/treatment prior to certolizumab initiation. Monitor for clinical and laboratory signs of active infection during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness and urticaria have been reported (rarely) with treatment. Some of these reactions have occurred after the first dose. Discontinue and do not resume therapy if hypersensitivity occurs. Use with caution in patients who have experienced hypersensitivity with other TNF blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunogenicity: A small number of patients (8%) develop antibodies to certolizumab during therapy. Antibody-positive patients may have an increased incidence of adverse events (including injection site pain/erythema, abdominal pain, and erythema nodosum).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients treated with certolizumab are at increased risk for developing serious infections, which may result in hospitalization or death; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving certolizumab. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks vs benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.</b> The elderly, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at a greater risk of infection. Consider risks vs benefits prior to initiating therapy in patients with a history of opportunistic infection; patients who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; and patients with underlying conditions, which may predispose them to infection. Do not initiate certolizumab therapy with active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescent patients receiving TNF-blocking agents.</b> <b>Certolizumab is not indicated for use in pediatric patients. </b>Approximately half of the malignancies reported in children were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included malignancies not typically observed in this population. The onset of malignancy was after a median of 30 months (range: 1 to 84 months) after the initiation of the TNF-blocking agent. Use of TNF blockers may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. Chronic immunosuppressant therapy use may be a predisposing factor for malignancy development; rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, including certolizumab, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis, most of whom had received concurrent treatment with azathioprine and/or 6-mercaptopurine. Melanoma and Merkel cell carcinoma have been reported with TNF-blocking agents including certolizumab. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk for skin cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warning]: Tuberculosis (disseminated or extrapulmonary disease) has been reported; both reactivation of latent infection and new infections have been reported. Patients should be tested for latent tuberculosis infection before and during therapy; consider treatment of latent tuberculosis prior to certolizumab treatment. Monitor for development of tuberculosis during and after treatment, including  patients with initial negative skin tests.</b> Use with caution in patients who have resided in regions where tuberculosis is endemic. Consider antituberculosis treatment prior to initiation of certolizumab in patients with a history of latent or active tuberculosis if adequate treatment course cannot be confirmed, and for patients with risk factors for tuberculosis despite a negative test. Strongly consider tuberculosis in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use with caution in heart failure patients; worsening heart failure and new-onset heart failure have been reported with TNF blockers, including certolizumab; monitor closely. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use has not been studied in patients with renal impairment; however, the pharmacokinetics of the pegylated (polyethylene glycol) component may be dependent on renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients, may be at higher risk for infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Malignancies have been reported among children and adolescents receiving TNF-blocking agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be up to date with all immunizations before initiating therapy; patients may receive vaccines other than live or live attenuated vaccines during therapy. There is no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299004\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027484\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8644&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the immunosuppressive effect of Certolizumab Pegol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Certolizumab Pegol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RiTUXimab: May enhance the immunosuppressive effect of Certolizumab Pegol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027454\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Certolizumab was found to cross the human placenta. Serum concentrations in 12 infants of 10 mothers were &ge;75% lower than the maternal serum at delivery (last maternal dose of 400 mg given 5 to 42 days prior to birth). Although placental transfer was low, infants may have a slower rate of elimination than adults. In 1 infant, certolizumab serum concentrations decreased from 1.02 to 0.84 mcg/mL over 4 weeks. Adverse events were not reported. The safety of administering live or live-attenuated vaccines to exposed infants is not known. If a biologic agent such as certolizumab is needed to treat inflammatory bowel disease during pregnancy, it is recommended to hold therapy after 30 weeks gestation (Habal 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to certolizumab during pregnancy in the MotherToBaby Pregnancy Studies by contacting the Organization of Teratology Information Specialists (OTIS) (877-311-8972) or http://mothertobaby.org/pregnancy-studies/.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20134461\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if certolizumab  is excreted in breast milk.  According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027513\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) including periodic skin examinations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The American Gastroenterological Association suggests reactive therapeutic drug monitoring to guide treatment changes in adult patients treated with certolizumab for active inflammatory bowel disease (Feuerstein 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027505\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Certolizumab is a pegylated humanized antibody Fab&rsquo; fragment of tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Certolizumab binds to and selectively neutralizes human TNF-alpha activity. (Elevated levels of TNF-alpha have a role in the inflammatory process associated with Crohn disease and in joint destruction associated with rheumatoid arthritis.) Since it is not a complete antibody (lacks Fc region), it does not induce complement activation, antibody-dependent cell-mediated cytotoxicity, or apoptosis. Pegylation of certolizumab allows for delayed elimination and therefore an extended half-life.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027491\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 6 to 8 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: ~80% (range: 76% to 88%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 54 to 171 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321823\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Cimzia Prefilled Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 X 200 mg/mL (1): $4,853.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Cimzia Starter Kit Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 X 200 mg/mL (1): $4,853.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Cimzia Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 X 200 mg (1): $4,853.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390217\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cimzia (AE, AR, AT, AU, BB, BE, BR, CH, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, HU, IE, IL, JP, LB, LT, LU, MT, MX, MY, NI, NL, NO, NZ, PA, PL, PT, QA, RO, SE, SG, SI, SK, SV, TR);</li>\n      <li>Perstymab PFS (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cimzia (certolizumab pegol) [prescribing information]. Smyrna, GA: UCB Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cimzia (certolizumab pegol) [product monograph]. Oakville, Ontario, Canada: UCB Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-&alpha; biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1464-1478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/24267475 /pubmed\" target=\"_blank\" id=\"24267475 \">24267475 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dommasch E and Gelfand JM, &ldquo;Is There Truly a Risk of Lymphoma From Biologic Therapies?&rdquo; <i>Dermatol Ther</i>, 2009, 22 (5):418-30.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/28780013/pubmed\" target=\"_blank\" id=\"28780013\">28780013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleischmann R, Vencovsky J, van Vollenhoven RF, et al, &ldquo;Efficacy and Safety of Certolizumab Pegol Monotherapy Every 4 Weeks in Patients With Rheumatoid Arthritis Failing Previous Disease-Modifying Antirheumatic Therapy: The FAST4WARD Study,&rdquo; <i>Ann Rheum Dis</i>, 2009, 68(6):805-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/19015206/pubmed\" target=\"_blank\" id=\"19015206\">19015206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. <i>Aliment Pharmacol Ther</i>. 2012;35(5):501-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls &amp; Alerts. Summary Safety Review - Tumour Necrosis Factor (TNF) alpha blockers (SIMPONI and CIMZIA) - Assessing the Potential Risk of Liver Inflammation (Autoimmune Hepatitis). Health Canada website. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/tnf-fnt-2-eng.php. Published October 25, 2016. Accessed November 3, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keystone E, Heijde D, Mason D Jr, et al, &ldquo;Certolizumab Pegol Plus Methotrexate is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study,&rdquo; <i>Arthritis Rheum</i>, 2008, 58(11):3319-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/18975346/pubmed\" target=\"_blank\" id=\"18975346\">18975346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo; <i>JAMA</i>, 2012, 308(9): 898-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/22948700/pubmed\" target=\"_blank\" id=\"22948700\">22948700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi: 10.1161/CIR.0000000000000426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo; <i>Eur J Gastroenterol Hepatol</i>, 2011, 23(12):1150-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/21941193/pubmed\" target=\"_blank\" id=\"21941193\">21941193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rutgeerts P, Schreiber S, Feagan B, et al, &ldquo;Certolizumab Pegol, a Monthly Subcutaneously Administered Fc-Free Anti-TNFalpha, Improves Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease,&rdquo; <i>Int J Colorectal Dis</i>, 2008, 23(3):289-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/18071721/pubmed\" target=\"_blank\" id=\"18071721\">18071721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, Feagan BG, Stoinov S, et al, &ldquo;Certolizumab Pegol for the Treatment of Crohn's Disease,&rdquo; <i>N Engl J Med</i>, 2007, 357(3):228-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/17634458/pubmed\" target=\"_blank\" id=\"17634458\">17634458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al, &ldquo;Maintenance Therapy With Certolizumab Pegol for Crohn's Disease,&rdquo; <i>N Engl J Med</i>, 2007, 357(3):239-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/17634459/pubmed\" target=\"_blank\" id=\"17634459\">17634459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schreiber S, Rutgeerts P, Fedorak RN, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease,&rdquo; <i>Gastroenterology</i>, 2005, 129(3):807-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/16143120/pubmed\" target=\"_blank\" id=\"16143120\">16143120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2015;41(10):972-979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/25756190/pubmed\" target=\"_blank\" id=\"25756190\">25756190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/22473917/pubmed\" target=\"_blank\" id=\"22473917\">22473917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smolen J, Landew&eacute; RB, Mease P, &ldquo;Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. A Randomised Controlled Trial,&rdquo; <i>Ann Rheum Dis</i>, 2009, 68(6):797-804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/19015207/pubmed\" target=\"_blank\" id=\"19015207\">19015207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-&alpha; biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1459-1463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/certolizumab-pegol-drug-information/abstract-text/24267474/pubmed\" target=\"_blank\" id=\"24267474\">24267474</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8644 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6027445\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6019485\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9477197\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6027450\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6027509\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6027510\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7822930\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682568\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20134470\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6027523\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6027448\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874551\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6027511\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6027452\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F24744596\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6027462\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6027458\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6027459\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299004\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6027484\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6027454\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20134461\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6027513\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6027505\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6027491\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321823\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390217\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8644|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=certolizumab-pegol-patient-drug-information\" class=\"drug drug_patient\">Certolizumab pegol: Patient drug information</a></li></ul></div></div>","javascript":null}